Sevabertinib
Drug Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Sevabertinib |
| Trade Name | Hyrnuo |
| Synonyms | BAY-2927088|BAY 2927088|BAY2927088 |
| Drug Descriptions |
Hyrnuo (sevabertinib) is a mutant-selective EGFR inhibitor with activity against EGFR exon 20 insertions, EGFR exon 19 deletions, EGFR L858R, and EGFR C797S, which potentially results in inhibition of tumor growth (European Journal of Cancer 174 (2022): S9-S10). Hyrnuo (sevabertinib) is FDA-approved for use in patients with non-squamous non-small cell lung cancer harboring ERBB2 (HER2) tyrosine kinase domain activating mutations (FDA.gov). |
| DrugClasses | EGFR Exon 20 Insertion Inhibitor 15 EGFR Inhibitor (Pan) 63 HER2 Inhibitor 44 |
| CAS Registry Number | NA |
| NCIT ID | C185187 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Sevabertinib | Sevabertinib | 0 | 3 |
CKB BOOST